Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection
Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection
The OrganoPlate® 2-lane 96 is a microfluidic cell culture platform that enables culturing and screening of a range of miniaturized 3D organs and tissue models. Here we describe the development of a functional 3D liver-on-a-chip model on the OrganoPlate®. The 3-liver cell type model was constructed by seeding differentiated induced pluripotent stem-cell derived hepatocytes (iHeps) in collagen extracellular matrix in the top channel of the chip, and endothelial and Kupffer cells in the bottom channel. Characterization of the model showed that the culture achieved a mature hepatocyte phenotype over time. The model was capable of detecting known hepatotoxins and four robust assays were identified and used in a compound library screen of 159 compounds. Identified toxic hits were ranked in hepatotoxicity by a composite score and a follow-up dose-response assessment was conducted. The platform’s compatibility with standard laboratory equipment and automation makes this liver-on-a-chip model amenable to highthroughput screening. This physiologically relevant model enables hepatotoxicity testing and provides valuable insight into drug efficacy studies for liver diseases.
Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection
The OrganoPlate® 2-lane 96 is a microfluidic cell culture platform that enables culturing and screening of a range of miniaturized 3D organs and tissue models. Here we describe the development of a functional 3D liver-on-a-chip model on the OrganoPlate®. The 3-liver cell type model was constructed by seeding differentiated induced pluripotent stem-cell derived hepatocytes (iHeps) in collagen extracellular matrix in the top channel of the chip, and endothelial and Kupffer cells in the bottom channel. Characterization of the model showed that the culture achieved a mature hepatocyte phenotype over time. The model was capable of detecting known hepatotoxins and four robust assays were identified and used in a compound library screen of 159 compounds. Identified toxic hits were ranked in hepatotoxicity by a composite score and a follow-up dose-response assessment was conducted. The platform’s compatibility with standard laboratory equipment and automation makes this liver-on-a-chip model amenable to highthroughput screening. This physiologically relevant model enables hepatotoxicity testing and provides valuable insight into drug efficacy studies for liver diseases.
Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection
The OrganoPlate® 2-lane 96 is a microfluidic cell culture platform that enables culturing and screening of a range of miniaturized 3D organs and tissue models. Here we describe the development of a functional 3D liver-on-a-chip model on the OrganoPlate®. The 3-liver cell type model was constructed by seeding differentiated induced pluripotent stem-cell derived hepatocytes (iHeps) in collagen extracellular matrix in the top channel of the chip, and endothelial and Kupffer cells in the bottom channel. Characterization of the model showed that the culture achieved a mature hepatocyte phenotype over time. The model was capable of detecting known hepatotoxins and four robust assays were identified and used in a compound library screen of 159 compounds. Identified toxic hits were ranked in hepatotoxicity by a composite score and a follow-up dose-response assessment was conducted. The platform’s compatibility with standard laboratory equipment and automation makes this liver-on-a-chip model amenable to highthroughput screening. This physiologically relevant model enables hepatotoxicity testing and provides valuable insight into drug efficacy studies for liver diseases.
Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection
The OrganoPlate® 2-lane 96 is a microfluidic cell culture platform that enables culturing and screening of a range of miniaturized 3D organs and tissue models. Here we describe the development of a functional 3D liver-on-a-chip model on the OrganoPlate®. The 3-liver cell type model was constructed by seeding differentiated induced pluripotent stem-cell derived hepatocytes (iHeps) in collagen extracellular matrix in the top channel of the chip, and endothelial and Kupffer cells in the bottom channel. Characterization of the model showed that the culture achieved a mature hepatocyte phenotype over time. The model was capable of detecting known hepatotoxins and four robust assays were identified and used in a compound library screen of 159 compounds. Identified toxic hits were ranked in hepatotoxicity by a composite score and a follow-up dose-response assessment was conducted. The platform’s compatibility with standard laboratory equipment and automation makes this liver-on-a-chip model amenable to highthroughput screening. This physiologically relevant model enables hepatotoxicity testing and provides valuable insight into drug efficacy studies for liver diseases.
Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection
The OrganoPlate® 2-lane 96 is a microfluidic cell culture platform that enables culturing and screening of a range of miniaturized 3D organs and tissue models. Here we describe the development of a functional 3D liver-on-a-chip model on the OrganoPlate®. The 3-liver cell type model was constructed by seeding differentiated induced pluripotent stem-cell derived hepatocytes (iHeps) in collagen extracellular matrix in the top channel of the chip, and endothelial and Kupffer cells in the bottom channel. Characterization of the model showed that the culture achieved a mature hepatocyte phenotype over time. The model was capable of detecting known hepatotoxins and four robust assays were identified and used in a compound library screen of 159 compounds. Identified toxic hits were ranked in hepatotoxicity by a composite score and a follow-up dose-response assessment was conducted. The platform’s compatibility with standard laboratory equipment and automation makes this liver-on-a-chip model amenable to highthroughput screening. This physiologically relevant model enables hepatotoxicity testing and provides valuable insight into drug efficacy studies for liver diseases.
Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection
The OrganoPlate® 2-lane 96 is a microfluidic cell culture platform that enables culturing and screening of a range of miniaturized 3D organs and tissue models. Here we describe the development of a functional 3D liver-on-a-chip model on the OrganoPlate®. The 3-liver cell type model was constructed by seeding differentiated induced pluripotent stem-cell derived hepatocytes (iHeps) in collagen extracellular matrix in the top channel of the chip, and endothelial and Kupffer cells in the bottom channel. Characterization of the model showed that the culture achieved a mature hepatocyte phenotype over time. The model was capable of detecting known hepatotoxins and four robust assays were identified and used in a compound library screen of 159 compounds. Identified toxic hits were ranked in hepatotoxicity by a composite score and a follow-up dose-response assessment was conducted. The platform’s compatibility with standard laboratory equipment and automation makes this liver-on-a-chip model amenable to highthroughput screening. This physiologically relevant model enables hepatotoxicity testing and provides valuable insight into drug efficacy studies for liver diseases.
Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection
The OrganoPlate® 2-lane 96 is a microfluidic cell culture platform that enables culturing and screening of a range of miniaturized 3D organs and tissue models. Here we describe the development of a functional 3D liver-on-a-chip model on the OrganoPlate®. The 3-liver cell type model was constructed by seeding differentiated induced pluripotent stem-cell derived hepatocytes (iHeps) in collagen extracellular matrix in the top channel of the chip, and endothelial and Kupffer cells in the bottom channel. Characterization of the model showed that the culture achieved a mature hepatocyte phenotype over time. The model was capable of detecting known hepatotoxins and four robust assays were identified and used in a compound library screen of 159 compounds. Identified toxic hits were ranked in hepatotoxicity by a composite score and a follow-up dose-response assessment was conducted. The platform’s compatibility with standard laboratory equipment and automation makes this liver-on-a-chip model amenable to highthroughput screening. This physiologically relevant model enables hepatotoxicity testing and provides valuable insight into drug efficacy studies for liver diseases.
Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection
The OrganoPlate® 2-lane 96 is a microfluidic cell culture platform that enables culturing and screening of a range of miniaturized 3D organs and tissue models. Here we describe the development of a functional 3D liver-on-a-chip model on the OrganoPlate®. The 3-liver cell type model was constructed by seeding differentiated induced pluripotent stem-cell derived hepatocytes (iHeps) in collagen extracellular matrix in the top channel of the chip, and endothelial and Kupffer cells in the bottom channel. Characterization of the model showed that the culture achieved a mature hepatocyte phenotype over time. The model was capable of detecting known hepatotoxins and four robust assays were identified and used in a compound library screen of 159 compounds. Identified toxic hits were ranked in hepatotoxicity by a composite score and a follow-up dose-response assessment was conducted. The platform’s compatibility with standard laboratory equipment and automation makes this liver-on-a-chip model amenable to highthroughput screening. This physiologically relevant model enables hepatotoxicity testing and provides valuable insight into drug efficacy studies for liver diseases.